|
|
|
OTC Medicines > Cough and Cold > Asthma, Cold Medication Rubs
|
| Primatene Mist Bronchial Asthma Complete Relief - 1/2Oz |
| Primatene Mist Bronchial Asthma Complete Relief is temporarily relieves shortness of breath and tightness of chest. |
| Ships within 24 hours. |
|
| Primatene |
|
|
| Be the first to review this product |
|
|
|
In Stock : |
Yes |
|
List Price : |
$28.79 |
|
Your Price : |
$22.99 |
|
|
|
|
Quantity : |
|
|
|
|
|
|
|
|
| Part No : 105361 |
UPC : 305732910208 |
|
|
|
|
| Description |
|
MANUFACTURER: WYETH CONSUMER.
INDICATIONS:
Primatene Mist Bronchial Asthma Complete Relief is temporarily relieves shortness of breath, tightness of chest, and wheezing due to bronchial asthma. Eases breathing for asthma patients by reducing spasms of bronchial muscles.
INGREDIENTS:
Active Ingredients:
Epinephrine (5. 5 mg/mL).
Inactive Ingredients:
Alcohol, Ascorbic Acid, Fluorocarbons, Water.
DIRECTIONS:
Adults and children 4 years of age and older: start with one inhalation, then wait 1 minute. If not relieved, use once more.
- Do not use again for at least 3 hours.
- Children under 4 years of age: consult a doctorThe use of this product by children should be supervised by an adult. See insert for mouthpiece use and care instructions.
-
Store at room temperature, between 15-25C (59-77F)Contains no sulfites.
WARNINGS:
- For inhalation only.
Do not use: unless a diagnoses of asthma has been made a doctor. if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.
- Ask a doctor before use if you have heart disease, thyroid disease, diabetes, high blood pressure, ever been hospitalized for asthma, trouble urinating due to an enlarged prostate gland.
-
Ask a doctor or pharmacist before use if you are taking any prescription drug for asthma.
|
|
|
|
|
|
|
|
